Wirostko Barbara M

Wirostko Barbara M, Roy Chowdhury Uttio, Brandano Lisa A, Casale Ralph A, DeWalt Daniel J, Rykard Laura R et al.

QLS-111, a novel potassium channel opener, safely and effectively lowered eye pressure in animals, showing additive benefits with existing glaucoma drugs by reducing episcleral venous pressure, promising a new treatment.

Kazemi Arash, Roy Chowdhury Uttio, Fautsch Michael P, Htoo Thurein M, Wirostko Barbara M, Hodge David O et al.

This study found episcleral venous pressure (EVP) and intraocular pressure (IOP) both peak in the morning and are correlated. Reducing EVP could be a key target for IOP regulation.

Pervan-Steel Cynthia L, Roy Chowdhury Uttio, Sookdeo Hemchand K, Casale Ralph A, Dosa Peter I, Htoo Thurein M et al.

QLS-101, a novel prodrug, effectively lowered eye pressure in mice for 24 hours after daily topical application, converting to its active form in human eye tissues. This offers a new glaucoma treatment.

Levin Ariana M, Chaya Craig J, Kahook Malik Y, Wirostko Barbara M

Anti-VEGF injections cause common, transient IOP spikes. Managing these, especially in glaucoma-risk patients, is crucial but lacks standard guidelines, impacting retinal ganglion cell health.

Mathew Sunu, Harris Alon, Ridenour Colin M, Wirostko Barbara M, Burgett Kendall M, Scripture Molly D et al.

Mathew Sunu, Harris Alon, Ridenour Colin M, Wirostko Barbara M, Burgett Kendall M, Scripture Molly D et al.

Managing glaucoma in pregnancy is challenging. Pregnant women have lower intraocular pressure, but medication risks to the fetus necessitate balancing maternal optic nerve protection with avoiding harmful interventions.

Morshedi R Grant, Ricca Aaron M, Wirostko Barbara M

This review found anti-VEGF injections can cause ocular hypertension, proposing a novel mechanism: reduced nitric oxide in the eye may constrict the drainage system, increasing pressure. This highlights a serious side effect needing further study.

DeMill David L, Wirostko Barbara M, Nelson Lindsay A, Stewart William C

Stewart William C, DeMill D L, Wirostko Barbara M, Nelson Lindsay A, Stewart Jeanette A

This review found that including pigment dispersion or exfoliation glaucoma patients in clinical trials had a small, but statistically significant, impact on baseline IOP, suggesting minimal clinical influence on overall trial results.

Prendes Mark A, Harris Alon, Wirostko Barbara M, Gerber Austin L, Siesky Brent

This review highlights TGF-β's key role in glaucoma, causing elevated intraocular pressure via trabecular meshwork changes. Targeting TGF-β pathways offers a promising new therapeutic strategy.

Wirostko Barbara M, Tressler Charles, Hwang Lie-Ju, Burgess Gary, Laties Alan M

Chronic sildenafil for pulmonary hypertension showed no significant long-term ocular harm, including IOP or visual function, but some dose-related visual disturbances and rare retinal hemorrhages occurred, indicating overall ocular safety for chronic use.